A comprehensive analysis of the miraculous effects and indications of Seleniso (Silvio)

Selinexor (trade name: Silvio) is the world's first selective inhibitor of nuclear export (Selective Inhibitor of Nuclear Export, referred to as SINE). It blocks the function of multiple tumor suppressor proteins (such as p53, p21, p27) by inhibiting the function of nuclear export protein XPO1 , etc.) are transported out of the cell nucleus, allowing these tumor suppressor proteins to function again in the cell nucleus, inducing cancer cell apoptosis and inhibiting their proliferation. Compared with traditional chemotherapy or other targeted drugs, the mechanism of selinesol is extremely innovative and is considered to have opened up a new direction in tumor treatment.

Selinesol's main clinical applications focus on hematological malignancies. The United States FDA has approved it in combination with dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma (MM), and has also been approved in combination with other drugs to treat diffuse major B cell lymphoma (DLBCL). Clinical trials have shown that selinesol can significantly improve the response rate in patients with multiple myeloma, and some patients can achieve longer-term disease control, bringing new treatment options to advanced or drug-resistant patients.

In addition to hematological malignancies, selinesol has also shown potential in the treatment of solid tumors. A number of clinical trials are currently exploring its efficacy in solid tumors such as ovarian cancer, sarcoma, pancreatic cancer, and breast cancer. Since the XPO1 protein is generally highly expressed in a variety of cancer cells, selinesol can theoretically be widely used in the treatment of different types of tumors. Although efficacy data on solid tumors are still accumulating, its "multi-pathway, multi-target" mode of action provides more hope for patients with refractory cancers.

Taken together, Seleniso's "miraculous effect" is mainly reflected in its ability to restore the body's natural anti-cancer ability through a new mechanism. At present, it has become an important treatment option for multiple myeloma and DLBCL , especially for patients after failure of traditional treatments. With the continuous deepening of clinical research, selinesol is expected to expand to more tumor indications in the future, and may form a combination program with immunotherapy and other targeted drugs to further improve the efficacy. Today, with the continuous development of precision medicine, selinesol is regarded as an "emerging star drug" with great potential.

Reference link:https://www.drugs.com